Lv11
30 积分 2025-04-26 加入
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials
2天前
已完结
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial
2天前
已完结
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine
2天前
已完结
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder
15天前
已完结
569. Preclinical Pharmacology of DLX-2270: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Schizophrenia
24天前
已完结
[Guidelines for the diagnosis and treatment of insomnia disorder (2025 edition)]
1个月前
已完结
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
1个月前
已完结
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia
1个月前
已完结
Xanomeline/Trospium Chloride: First Approval
1个月前
已完结
皖公网安备34019202002308
